BeatO Raises INR 42 Cr Funding From W Health Ventures, PharmEasy
Healthtech startup BeatO, which specialises in diabetes-related solutions, has raised INR 42 Cr (roughly $5.8 Mn) in funding led by US-based venture capital firm W Health Ventures. The funding also saw participation from healthtech unicorn PharmEasy, Merisis VP and existing investors Orios VP, Leo Capital and others.
With this new funding, BeatO has raised INR 75 Cr over the last year across its Series A and Pre-Series B rounds. The investment from PharmEasy comes after healthtech unicorn’s acquisition of diagnostics chain Thyrocare.
- The funds will be utilized across two key areas – growth in subscriber base across multiple channels and geographies, and product enhancement to provide care for other cardiometabolic conditions
- BeatO offers a comprehensive diabetes management and care platform via its glucose-monitoring solutions
- The Indian healthtech market is expected to reach a size of $21 Bn by 2025
The fresh funds will be utilised to fuel growth in the paying subscriber base across multiple channels and geographies as well as for product enhancement to cater to other cardiometabolic conditions besides diabetes.
Founded in 2015 by Yash Sehgal, Abhishek Kumar and Gautam Chopra, the company offers a digital care ecosystem for chronic condition management. Through a mobile app, the startup offers a comprehensive diabetes management and care platform via its glucose-monitoring solutions. It also offers diabetes-specific products such as snacks, specialty food and footwear, besides a marketplace of doctors, educators, diagnostics, medicines refills and insurance products.
